{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:47:21Z","timestamp":1778323641130,"version":"3.51.4"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:p>Mitochondria are promising drug target for cancer treatment. We previously demonstrated that a bi-gold compound BGC2a was more potent than the mono-gold drug auranofin in suppressing cancer cells due to increased gold atom number that led to higher drug accumulation in and thereby inhibition of mitochondria. To exploit the potential of this new strategy, we further designed and synthesized a series of bi-gold mitocans, the compounds targeting mitochondria. The results showed that most of the newly synthesized mitocans exhibited obviously lower IC<jats:sub>50<\/jats:sub> than auranofin, an old drug that is repurposed in clinical trials for cancer treatment. The best mitocan C3P4 was nearly 2-fold more potent than BGC2a in human non-small cell lung cancer A549 cells and mantle cell lymphoma Jeko-1 cells, exhibiting substantial colony formation-suppressing and tumor-suppressing effects in A549 cells xenograft model. C3P4 induced apoptosis in a dose-dependent manner and arrested cell cycle at G0\/G1 phase. The mechanistic study showed that C3P4 significantly increased the global reactive oxygen species and mitochondrial superoxide level, and reduced the mitochondrial membrane potential. C3P4 preferentially accumulated in mitochondria as measured by the gold content and substantially inhibited oxygen consumption rate and ATP production. These results further validated our hypothesis that targeting mitochondria would be promising to develop more potent anticancer agents. C3P4 may be further evaluated as a drug candidate for lung cancer treatment.<\/jats:p>","DOI":"10.3389\/fchem.2023.1292115","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T10:08:09Z","timestamp":1702289289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Synthesis and biological evaluation of novel bi-gold mitocans in lung cancer cells"],"prefix":"10.3389","volume":"11","author":[{"given":"Wenwen","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingbin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongliang","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.semcdb.2019.05.022","article-title":"Mitochondria as playmakers of apoptosis, autophagy and senescence","volume":"98","author":"Abate","year":"2019","journal-title":"Semin. Cell Dev. Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41580-019-0173-8","article-title":"Mitochondria as multifaceted regulators of cell death","volume":"21","author":"Bock","year":"2020","journal-title":"Nat. Rev. Mol. Cell Bio."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e01947","DOI":"10.1128\/AAC.01947-16","article-title":"Phase I clinical trial results of auranofin, a novel antiparasitic agent","volume":"61","author":"Capparelli","year":"2017","journal-title":"Antimicrob. Agents Ch."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1089\/ars.2017.7485","article-title":"Redox paradox: a novel approach to therapeutics-resistant cancer","volume":"29","author":"Chaiswing","year":"2018","journal-title":"Antioxid. Redox Sign."},{"key":"B5","doi-asserted-by":"publisher","first-page":"12169","DOI":"10.3390\/ijms232012169","article-title":"Developing Bi-gold compound BGC2a to target mitochondria for the elimination of cancer cells","volume":"23","author":"Cui","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.11.001","article-title":"Modulating ROS to overcome multidrug resistance in cancer","volume":"41","author":"Cui","year":"2018","journal-title":"Drug resist. Update"},{"key":"B8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.4155\/fmc-2017-0011","article-title":"Targeting cancer cell mitochondria as a therapeutic approach: recent updates","volume":"9","author":"Cui","year":"2017","journal-title":"Future Med. Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4155\/fmc-2018-0403","article-title":"Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible","volume":"11","author":"Cui","year":"2019","journal-title":"Future Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"7941","DOI":"10.3390\/ijms21217941","article-title":"Mitocans revisited: mitochondrial targeting as efficient anti-cancer therapy","volume":"21","author":"Dong","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bcp.2009.07.023","article-title":"Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase","volume":"79","author":"Gandin","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00775-016-1338-y","article-title":"Novel antitumor adamantane-azole gold(I) complexes as potential inhibitors of thioredoxin reductase","volume":"21","author":"Garcia","year":"2016","journal-title":"J. Biol. Inorg. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"vdab075","DOI":"10.1093\/noajnl\/vdab075","article-title":"A phase Ib\/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3","volume":"3","author":"Halatsch","year":"2021","journal-title":"Neurooncol Adv."},{"key":"B14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF03214684","article-title":"The role of gold in alchemy. Part I","volume":"18","author":"Kauffman","year":"1985","journal-title":"Gold Bull."},{"key":"B15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12272-023-01438-1","article-title":"Anti-fibrotic effect of aurocyanide, the active metabolite of auranofin","volume":"46","author":"Kim","year":"2023","journal-title":"Arch. Pharm. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1177271918755391","DOI":"10.1177\/1177271918755391","article-title":"Reactive oxygen species: a key constituent in cancer survival","volume":"13","author":"Kumari","year":"2018","journal-title":"Biomark. Insights"},{"key":"B17","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2174\/187152011797927670","article-title":"Phosphine-gold(I) compounds as anticancer agents: general description and mechanisms of action","volume":"11","author":"Lima","year":"2011","journal-title":"Anti-Cancer Agent Me"},{"key":"B18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.mito.2021.11.002","article-title":"Targeting the redox imbalance in mitochondria: a novel mode for cancer therapy","volume":"62","author":"Mani","year":"2022","journal-title":"Mitochondrion"},{"key":"B19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.devcel.2011.06.017","article-title":"Mitochondria in apoptosis: bcl-2 family members and mitochondrial dynamics","volume":"21","author":"Martinou","year":"2011","journal-title":"Dev. Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1021\/jm00152a009","article-title":"Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes","volume":"29","author":"Mirabelli","year":"1986","journal-title":"J. Med. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20081386","article-title":"How mitochondria produce reactive oxygen species","volume":"417","author":"Murphy","year":"2009","journal-title":"Biochem. J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrd.2018.174","article-title":"Mitochondria as a therapeutic target for common pathologies","volume":"17","author":"Murphy","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jinorgbio.2014.01.009","article-title":"Insights on the mechanism of thioredoxin reductase inhibition by gold N-heterocyclic carbene compounds using the synthetic linear selenocysteine containing C-terminal peptide hTrxR(488-499): an ESI-MS investigation","volume":"136","author":"Pratesi","year":"2014","journal-title":"J. Inorg. Biochem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-1-4939-7401-6_8","article-title":"In vitro tumorigenic Assay: colony forming Assay for cancer stem cells","volume":"1692","author":"Rajendran","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2174\/157489206778776952","article-title":"Mitocans: mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents","volume":"1","author":"Ralph","year":"2006","journal-title":"Recent Pat. Anti-Canc"},{"key":"B26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/978-981-10-7757-9_7","article-title":"Mitochondrial respiratory chain complexes","volume":"87","author":"Sousa","year":"2018","journal-title":"Subcell. Biochem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/antiox11050971","article-title":"Auranofin and pharmacologic ascorbate as radiomodulators in the treatment of pancreatic cancer","volume":"11","author":"Steers","year":"2022","journal-title":"Antioxidants-Basel"},{"key":"B28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.chest.2019.08.2182","article-title":"Mitochondria and critical illness","volume":"157","author":"Supinski","year":"2019","journal-title":"Chest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"15712","DOI":"10.3390\/ijms232415712","article-title":"Menadione potentiates auranofin-induced glioblastoma cell death","volume":"23","author":"Szeliga","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrm2952","article-title":"Mitochondria and cell death: outer membrane permeabilization and beyond","volume":"11","author":"Tait","year":"2010","journal-title":"Nat. Rev. Mol. Cell Bio."},{"key":"B31","doi-asserted-by":"publisher","first-page":"627837","DOI":"10.3389\/fphys.2021.627837","article-title":"Mitochondrial reactive oxygen species and their contribution in chronic kidney disease progression through oxidative stress","volume":"12","author":"Tirichen","year":"2021","journal-title":"Front. Physiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1021\/acsinfecdis.9b00505","article-title":"Preclinical gold complexes as oral drug candidates to treat leishmaniasis are potent trypanothione reductase inhibitors","volume":"6","author":"Tunes","year":"2020","journal-title":"Acs Infect. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S2213-2600(20)30448-3","article-title":"Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial","volume":"9","author":"Wallis","year":"2021","journal-title":"Lancet Resp. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41467-018-02915-8","article-title":"Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1039\/c9md00572b","article-title":"TPP-based mitocans: a potent strategy for anticancer drug design","volume":"11","author":"Wang","year":"2020","journal-title":"Rsc Med. Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3390\/molecules23061410","article-title":"Gold-based medicine: a paradigm shift in anti-cancer therapy?","volume":"23","author":"Yeo","year":"2018","journal-title":"Molecules"}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2023.1292115\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T10:08:12Z","timestamp":1702289292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2023.1292115\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":35,"alternative-id":["10.3389\/fchem.2023.1292115"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2023.1292115","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"article-number":"1292115"}}